Background. The Clinical and Laboratory Standards Institute (CLSI) revised the carbapenem breakpoints for Enterobacteriaceae in 2010. The number of hospitals that adopted revised breakpoints and the clinical impact of delayed adoption has not been explored.
Carbapenem-resistant Enterobacteriaceae (CRE) have become an urgent threat in the United States [1, 2] . Of particular concern, the Centers for Disease Control and Prevention (CDC) have reported a steady increase in burden of disease from CRE [3, 4] and CRE are now endemic in many parts of the United States [5] . The attributable mortality from CRE infections is up to 50%, and there are limited available treatment options for CRE infections [6, 7] . Carbapenem resistance among Enterobacteriaceae may be due to the presence of a carbapenemase enzyme capable of hydrolyzing the carbapenems, commonly referred to as carbapenemase-producing (CP) CRE. Alternatively, carbapenem resistance may emerge from a combination of other mechanisms of resistance, including altered permeability, efflux, and noncarbapenemase beta-lactamases. This latter group is commonly referred to as non-CP CRE. CP-CRE are of most concern from an epidemiological perspective because carbapenemase genes reside on plasmids that are readily disseminated to other bacterial isolates. Accurate detection of CP-CRE is enhanced by use of current vs historical Clinical and Laboratory Standards Institute (CLSI) breakpoints, and use of current breakpoints is critical to predicting the efficacy of carbapenems for patient treatment.
Historically, laboratories used supplemental tests to detect carbapenemases if an Enterobacteriaceae isolate had an elevated carbapenem minimum inhibitory concentration (MIC) that was within the susceptible interpretive category (Table 1) . If a carbapenemase was detected, laboratories were instructed by the CLSI to report all carbapenems as resistant, regardless of the carbapenem MIC. CLSI revised the carbapenem breakpoints for the Enterobacteriaceae in 2010 (Table 1) , and the US Food and Drug Administration (FDA) subsequently updated carbapenem product labeling to include the revised breakpoints [8] [9] [10] [11] . The revised CLSI-FDA breakpoints are based on the expected outcome of carbapenem therapy [12] and do not require use of carbapenemase tests. As such, CLSI advises laboratories that use the revised (current) breakpoints to not edit carbapenem MICs to resistant when reporting patients' results if an isolate is found to harbor a carbapenemase. The Infectious Diseases Society of America issued an alert to members, endorsing the breakpoints and encouraging their use by US hospitals [13] . Similarly, the CDC revised its CRE definition based on the CLSI breakpoints [14] .
Almost all laboratories in the United States rely on commercial automated antimicrobial susceptibility test (AST) systems as the sole method of routine testing. Unfortunately, manufacturers of these systems have lagged in updating to the new breakpoints, despite the passing of more than 7 years since their approval (Table 2) . Laboratories may manually adjust breakpoints in their AST system. However, because this is off-label, they must first perform verification studies to document that the AST system performs adequately with the revised breakpoints. Verification studies are labor and time intensive.
To quantify the use of current carbapenem breakpoints for Enterobacteriaceae, we evaluated the status of carbapenem testing for Enterobacteriaceae by clinical laboratories in California. This evaluation was performed via use of data from the California Antimicrobial Resistance Laboratory Network Assessment (CARLA) survey. To estimate the clinical impact of miscategorization of Enterobacteriaceae isolates, we evaluated carbapenem susceptibility among a collection of 417 California CRE isolates using both historical (ie, outdated) and current carbapenem breakpoints and polymerase chain reaction (PCR) assay for carbapenemase genes.
METHODS

California Antimicrobial Resistance Laboratory Network Assessment Survey
CARLA was a cross-sectional, voluntary online survey of all microbiology laboratories that serve acute care hospitals and long-term acute care hospitals (LTAC) in California. The survey targeted directors of the clinical microbiology laboratories or microbiology laboratory staff. The survey was conducted using Survey Monkey in fall 2015 to spring 2016. Survey questions and responses were based on laboratory practices in place at the time of the survey. An a priori response threshold of 60% was used to ensure a representative sample, and nonrespondents were contacted by phone in attempts to encourage participation and enhance the response rate. Responses were aggregated, and data were evaluated by hospital. Hospital size and patient volume data were obtained from the National Healthcare Safety Network 2015 Annual Hospital Survey.
Estimation of the Clinical Impact of Using Historical Breakpoints
Carbapenem MIC results from CRE isolates tested by the University of California-Los Angeles (UCLA) Clinical Microbiology Laboratory were examined to assess the ability of current vs historical breakpoints to accurately detect CP-CRE. The UCLA laboratory systematically saved all CRE isolates from January 2013 to February 2017 as part of standard operating procedures. All isolates were tested against ertapenem, meropenem, and imipenem by the CLSI reference broth microdilution (BMD) method at the time of isolation from patients on panels prepared in-house. Urine isolates were tested using the Vitek 2 (bioMerieux, Durham, North Carolina), and all isolates with imipenem or meropenem MIC >1 µg/mL were confirmed using BMD. Isolates with confirmed imipenem and/or meropenem MIC >1 µg/mL were tested for the presence of carbapenemase genes. Isolates of Proteus, Providencia, and Morganella with imipenem MICs >1 µg/ mL but meropenem MIC <2 µg/mL were excluded from analysis, as this phenotype is attributable to intrinsic imipenem resistance in these genera [15] . To identify the presence of a carbapenemase gene, real-time PCR assay was performed for Klebsiella pneumoniae carbapenemase (KPC), New-Delhi metalo-beta-lactamase (NDM), Serratia marcescens enzyme (SME), imipenem-hydrolyzing beta-lactamase (IMP), Verona integrin-encoded metallo-beta-lactamase, or oxacillinase (OXA) carbapenemases, as described previously [16, 17] . Carbapenem MICs were interpreted according to the current CLSI M100S, 27th Edition, [8] and historical M100-S19 breakpoints [18] . Only 1 isolate of a given species per patient per year was included in this analysis.
RESULTS
Status of Breakpoint Adoption for Enterobacteriaceae in California
We sent out surveys to 392 hospitals and LTACs, of which 264 (67%) responded. These institutions used 129 unique clinical microbiology laboratories. Respondents included laboratory directors (n = 81, 63%), clinical laboratory scientists (n = 46, 37%), and infection preventionists (n = 1, 1%). The majority of laboratories used the Vitek 2 system for testing Enterobacteriaceae (n = 72, 56%). Thirty-seven (29%) used the MicroScan, 10 (8%) used the Phoenix, and 2 (2%) using the Sensititre. Laboratories that performed manual AST methods included disk diffusion (n = 3 [2%]), agar dilution (n = 1 [1%]), and CLSI reference broth microdilution (n = 1 [UCLA, 1%]). One laboratory did not perform susceptibility testing and 2 did not disclose the method of AST. Overall, 92/128 (72%) laboratories indicated they were using the current CLSI carbapenem breakpoints for Enterobacteriaceae. These included 48/72 (67%) that used Vitek 2, 24/37 (65%) that used MicroScan, 10/10 (100%) that used Phoenix, and 2/2 (100%) that used Sensititre (Table 3 ). All laboratories that performed manual tests such as agar dilution, disk diffusion, and reference BMD (n = 5) indicated they were using the current CLSI breakpoints, as did the 2 laboratories that did not disclose the AST method used. Time to implementation of the breakpoints by these laboratories, from the time they were published by CLSI in June 2010, varied for the 74 laboratories that disclosed this information from 0to 68 months (average, 41 months; median, 55 months; Figure 1 ).
Potential Impact of Using Historical Breakpoints
Over the surveillance period, 421 UCLA isolates met testing criteria for possible CP-CRE, of which 237 harbored a carbapenemase gene (56%) and were thus confirmed as CP-CRE. KPC was the most common carbapenemase encountered (n = 209, 88% of carbapenemase-producers; Table 4 ). NDM (n = 3), OXA-48-like (n = 18), SME (n = 5), and IMP (n = 2) carbapenemases were also observed. The most common species was Klebsiella pneumoniae (n = 198, 83%) followed by Citrobacter freundii (n = 10, 4%), Escherichia coli (n = 10, 4%), Serratia marcescens (n = 7, 3%), Klebsiella oxytoca (n = 5, 2%), and Enterobacter cloacae (n = 3, 1%). One carbapenemase producer of each Enterobacter aerogenes, Citrobacter spp., Raoultella, and Providencia rettgeri were observed (<1%).
Among the 237 CP-CRE, historical breakpoints categorized 8.9% as susceptible to ertapenem, 18.6% to imipenem, and 18.6% to meropenem (Table 4 ). In contrast, <1% of isolates with a PCR-proven carbapenemase gene were interpreted as susceptible to ertapenem or imipenem by the current CLSI breakpoints, and 2.9% were identified as susceptible to meropenem. In evaluating KPC-containing isolates, 10.1%, 12.0%, and 20.2% of isolates were interpreted as susceptible to ertapenem, imipenem, and meropenem, respectively, using the historical breakpoints. In contrast, 0.5%, 0.0%, and 3.4% were susceptible by the current breakpoints (Table 4 ). In addition, when using the historical breakpoints, 10.1% of carbapenemase producers and 10.6% of KPC producers were interpreted as susceptible to both imipenem and meropenem, and 6.8% of carbapenemase producers and 7.7% of KPC producers were susceptible to all 3 carbapenems. For those laboratories that did not perform carbapenemase testing prior to reporting results to the clinician, the historical breakpoints would lead to reporting up to 20.2% of KPC producers as susceptible to a carbapenem.
Status of Carbapenemase Testing
Laboratories were queried on the use of tests to detect the presence of carbapenemases among the Enterobacteriaceae. Overall, 94/128 (73%) of laboratories that responded indicated they performed carbapenemase testing, including 62 (66%) that performed testing in-house, 20 (21%) at a commercial reference laboratory, and 12 (13%) at a public health laboratory. Among laboratories that used the historical CLSI breakpoints that require supplemental testing for carbapenemase, 21 (60%) performed carbapenemase testing on-site, 5 at a public health laboratory (14%), 4 at a commercial reference laboratory (11%), and 5 did not perform carbapenemase testing at all (14%). Among laboratories that performed carbapenemase testing in-house, 52 (84%) performed the modified Hodge test (MHT), 11 (18%) PCR, 2 (3%) the Carba-NP, and 1 the carbapenem inactivation method (CIM; 2%). Three laboratories did not disclose the method of carbapenemase testing. Eight laboratories used more than 1 carbapenemase test method. Of those laboratories that performed carbapenemase testing either in-house or at a reference laboratory (n = 88), only 50 (57%) were compliant with CLSI guidance for how to use carbapenemase results when reporting carbapenem results on patient's isolates ( 
Potential Impact of Carbapenemase Testing
Among 237 UCLA isolates that harbored a carbapenemase gene, only 1 (0.4%) was susceptible to ertapenem or imipenem (Table 4 ) and 7 (3.0%) were susceptible to meropenem when evaluated by the current breakpoints. However, 24 (10.1%) isolates with a carbapenemase detected demonstrated MICs in the intermediate range (ie, 2 µg/mL) for imipenem and 13 (5.5%) for meropenem, by the current breakpoints. Imipenem MICs of 2 µg/mL were more common among isolates that were positive for IMP (1/2 isolates, 50.0%) or OXA-232 (12/41 isolates, 29.2%). In contrast, only 10 (4.2%) KPC-positive isolates and none of the NDM-or SME-positive isolates had imipenem MICs <4 µg/ mL. Meropenem MICs of 2 µg/mL occurred for 1 IMP producer Figure 1 . Timeline to implementation of current carbapenem breakpoints for Enterobacteriaceae in California (n = 128 laboratories).
(50.0%) and 12 KPC producers (5.8%). None of the OXA-232, SME, or NDM isolates had meropenem MICs of 2 µg/mL.
DISCUSSION
Our statewide survey in California demonstrated that more than a quarter of clinical laboratories use historical vs current CLSI-FDA carbapenem breakpoints for Enterobacteriaceae. Of particular concern, 5 laboratories indicated they had not updated the carbapenem breakpoints and did not perform any type of carbapenemase testing, which is recommended when using the historical breakpoints. These laboratories served hospitals ranging in size from 43 to 222 beds and are at significant risk of missing a clinical CRE isolate if encountered. Similarly, 3 laboratories that used the historical breakpoints indicated they performed carbapenemase testing but did not edit the carbapenem susceptible or intermediate results to resistant. Data from a large academic center demonstrate that not adopting current breakpoints is clinically meaningful, as nearly 20% of carbapenemase producers were classified as susceptible to carbapenems by historical breakpoints compared to 1%-3% with current breakpoints. Similar to our findings, Tamma and colleagues recently documented that of 109 CP-CRE, 22.9% had MICs ≤4 µg/mL to meropenem and 23.9% to imipenem, susceptible by the historical breakpoints [19] .
Failure to implement the current breakpoints has potential to not only negatively impact patient care but also impede infection control and public health endeavors to limit the spread of these organisms. Spread of CP-CRE appears to be driven by movement of patients through the healthcare system [20] [21] [22] [23] . At the local level, prevention of the spread of CP-CRE has been shown to be achievable through use of infection prevention bundles that include chlorhexidine bathing and strict isolation practices [24] . Computer model estimates suggest sustained impact requires coordinated regional response compared to individual hospital actions [22, 23] , all of which require timely and accurate detection of CP-CRE at the front line by clinical laboratory staff. Delays in implementing current CLSI standards likely negatively impact these efforts. For instance, a simulation model demonstrated that a 32-month delay in adopting the current carbapenem breakpoints was associated with an additional 1821 CP-CRE carriers in Orange County, California [25] . In this model, the presumed sensitivity for CP-CRE with the historical breakpoints was 80%, which is very similar to that observed in the present study. However, in our study, we found that implementation of the current breakpoints in California laboratories was delayed, on average, by 44 months (3.4 years), with a mode of 55 months (4.6 years). Furthermore, more than a quarter of hospitals continue to use the historical breakpoints. Delayed adoption of current CLSI-FDA breakpoints may have enhanced the spread of CP-CRE in this state and nation-wide, as patients move across state boundaries.
Among hospitals that still use the historical carbapenem breakpoints, the widespread use of the MHT (84% of laboratories) as a method to detect carbapenemases is concerning. The MHT is associated with significant performance issues, including false-negative results for isolates that harbor the NDM carbapenemase and false-positive results for species other than K. pneumoniae [26] . One study documented 55% false-positive MHT results for Enterobacter spp., 33% for Citrobacter spp., and 100% for E. coli [27] . As such, laboratories that use the MHT and edit carbapenem results to resistant, regardless of MIC, may be grossly overrepresenting both CP-and non-CP CRE incidence.
The widespread practice of using the MHT also poses clinical dilemmas. Potentially valuable data would be unavailable to the treating physician if the laboratory deletes the MIC values and edits carbapenem interpretations to resistant, as was done by 59% of laboratories that performed carbapenemase testing and used current breakpoints. Growing clinical experience and pharmacokinetic data suggest that time above MIC targets can be achieved using high-dose prolonged-infusion carbapenems when the carbapenem MIC is 2 µg/mL (ie, intermediate by the current breakpoints) [28] [29] [30] [31] . Further, combination antimicrobial regimens that include a carbapenem are more effective than combinations that do not include a carbapenem for the treatment of CRE, but efficacy may be limited when the carbapenem MIC is >4 µg/mL [32] [33] [34] . From our microbiologic testing results, the opportunity to provide imipenem-based salvage combination therapy would have been missed in 10% of KPC-, 50% of IMP-, and 29% of OXA-containing isolates if a susceptible or intermediate result would have been edited to resistant based on a positive MHT. Starting in 2018, the MHT will no longer be recommended by the CLSI for detection of carbapenemase, in favor of newer tests such as the modified CIM method that had not been endorsed by CLSI at the time of our study [35] .
Carbapenem resistance is complex, and all laboratories struggle with how to best detect and report organisms that harbor such resistance, often using convoluted testing algorithms to identify a CRE. Use of the current CLSI-FDA carbapenem breakpoints is currently the most effective way to detect carbapenem resistance in isolates of Enterobacteriaceae from diagnostic specimens [14] . The major impediment to laboratory use of the current CLSI breakpoints is the incomplete FDA clearance of automated AST systems with the current carbapenem breakpoints (Table 2) . To obtain clearance, diagnostic manufacturers may need to reformulate existing test panels and generate de novo data that demonstrate that their system performs accurately with the revised (current) breakpoints [36] . This activity requires not only prioritization and coordination by the diagnostic manufacturer but also a considerable financial investment. To date, the Phoenix and Sensititre systems are the only systems that have obtained FDA clearance for the revised ertapenem, imipenem, and meropenem breakpoints. These 2 systems have <10% of the market share in California (Table 2 ). At present, the FDA does not have a mechanism by which to compel the remaining 2 companies to revise the breakpoints used on their AST systems.
FDA requirements for clearance of existing systems with the revised breakpoints may be excessively stringent and, at the same time, modifications and clinical trials for AST systems in response to changes in breakpoints by the diagnostic manufacturers are too slow. The breakpoint challenge will continue to grow as CLSI and FDA continue to revise breakpoints-for example, there is ongoing discussion about a revision to fluoroquinolone breakpoints for the Enterobacteriaceae. The breakpoint dilemma is unique to the United States due to the current regulatory landscapelaboratories in Europe are using the same AST systems as those used in the United States, with Conformité Européenne mark (ie, European regulatory clearance for clinical testing) for the current CLSI breakpoints (which are the same as those endorsed by the European Committee on Antibiotic Susceptibility Testing). These systems have yet to obtain clearance for clinical use in the United States due, in part, to the stringent FDA review process. It is clear that coordination and change at the level of both diagnostic manufacturers and the FDA are needed.
Despite FDA clearance challenges, nearly three-quarters of laboratories in California use the current CLSI-FDA breakpoints for carbapenems and Enterobacteriaceae. According to federal regulations, laboratories can modify an FDA-cleared test, including applying a breakpoint that differs from the one cleared by FDA for the system, provided they have internally performed a verification study to ensure that the system works effectively with the modification. Many laboratories find it difficult to design and conduct these verification studies, but this should no longer be the case. Several resources exist to aid the laboratory with this endeavor, including the availability of the CDC-FDA Antimicrobial Resistance Isolate Bank organisms for use in verification studies (https://www.cdc.gov/drugresistance/resistance-bank/), guidance from the CLSI in the form of the M52 document [37] , and step-by-step verification plans available from the CLSI (www.clsi.org). Diagnostic manufacturers are typically able to guide laboratories with modification of the software on their AST system to the current breakpoints, even if the manufacturers have not obtained FDA clearance for these breakpoints.
Laboratories and clinicians need to understand the implications of not using current CLSI breakpoints, which, in our study, would have resulted in up to 20% of KPCs being categorized as falsely meropenem susceptible. Such miscategorization could lead to administration of inappropriate antibiotics and subsequent poor patient outcomes as well as undetected spread of CRE. Regulatory agencies need to develop a more streamlined process for AST manufacturers that allows them and clinical microbiology laboratories to rapidly adopt new breakpoints.
